About: acn

- 华堂宁(R)銷量同比增長108%，淨銷售額同比增長112%。醫保覆蓋持續擴大，二級和三級醫院處方量顯著增加，全面自主商業化成效顯著。- 與拜耳終止獨家推廣服務協議後，確認一次性遞延收入人民幣12.435億元，實現上半年盈利11.839億元，公司在業績期內首次實現盈利。- 在中國開展涉及80個中心和2000名2型糖尿病患者的真實世界研究，進一步證明多格列艾汀的廣泛適用性和安全性。- 多格列艾汀75mg（商品名：MYHOMSIS(R)，華領片TM）在香港遞交註冊申請，加速佈局大中華區及東南亞市場。- 毛利率顯著提升，生產規模與運營效率持續優化。上海，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（"公司"，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年6月30日止六個月（"報告期"）未經審核的綜合業績，以及公司上半年業務進展與未來展望。報告期內，公司核心產品华堂宁(R)（多格列艾汀片）商業化加速，自主運營能力顯著提升，研發進展順利推進，財務表現實現突破性成長，為長期可持續發展奠定了堅實基礎。華領醫藥創始人兼首席執行官陳力博士表示："2025 年上半年是華領醫藥轉型發展的關鍵階段。全面接管华堂宁(R)商業化後，公司憑藉自主搭建的銷售團隊，實現了銷量與收入的翻倍增長，印證了新的商業模式的有效性。我們還在中國香港遞交了新藥上市申請，為多格列艾汀從中國走向東南亞乃至全球市場奠定了基礎。同時，多格列艾汀在真實世界研究中持續展現出廣泛的治療潛力，也在基礎研究中發現了糖尿病緩解、認知改善、血脂改善和增肌等方面的新證據，進一步鞏固了華領醫藥在GKA研發和治療領域的全球領先地位。未來，華領醫藥將繼續深耕糖尿病和整個代謝疾病領域，通過創新研發與市場拓展的雙輪驅動，讓中國原創新藥惠及更多全球患者。"業務亮點與運營進展商業化轉型成效顯著，銷售與利潤雙增長- 2025年1月1日起，公司終止與拜耳的獨家推廣服務協議，全面接管华堂宁(R)在中國的商業化運營。報告期內，在與2024年同期的單價保持一致的情況下，华堂宁(R)銷量達176.4萬盒，同比增長108%；淨銷售額達2.174億元，同比增長112%。憑藉強勁的商業執行力和不斷提升的運營效率，公司邁向盈利。華領醫藥已順利過渡到全面自主商業化階段，也印證了日益增長的市場需求和自主銷售團隊的高效執行力。- 2024年被納入中國國家醫保藥品目錄(NRDL)後，2025年华堂宁(R)繼續受益於廣泛的醫保覆蓋，二級和三級醫院的處方量顯著增加，有助於提高患者的可及性和長期使用率。- 由於生產規模擴大和成本效率的提升，公司毛利率提升至54.2%，高於去年同期的46.5%。- 在銷售額同比增長112%的情況下，報告期內公司銷售費用為6420萬元，與去年同期相比僅增長5%，報告期內銷售費用約占總收入的29.5%，顯著低於去年同期的59.5%。這是因為，2025年上半年銷售費用構成與2024年同期相比發生了顯著變化：由公司在中國承擔华堂宁(R)的獨家商業化責任而直接產生銷售費用，而無需再向原商業化合作夥伴支付推廣費用。這反映出公司顯著的盈利向好趨勢，也表明了公司的業務戰略，即通過控制與华堂宁(R)商業化直接相關的銷售費用，以及最大限度地提高生產效率，來優化盈利能力。- 與拜耳終止獨家推廣服務協議後，公司確認一次性遞延收入12.435億元，向自主驅動增長轉型。華領醫藥首次實現半年稅前利潤11.839億元，這是華領醫藥邁向可持續盈利的關鍵里程碑。- 截至2025年6月30日，現金餘額為10.228億元，為公司未來的研發和商業化舉措奠定了堅實基礎。臨床研究持續深入，新證據支撐治療潛力- 公司正在推進多項上市後研究，以評估多格列艾汀在不同患者群體中的長期安全性和有效性，包括單藥治療以及與其它已經獲批的熱門降糖藥，如GLP-1受體激動劑、胰島素、DPP-4抑制劑和SGLT-2抑制劑的聯合用藥。這些研究正在為血糖控制、認知改善和糖尿病緩解潛力等提供新的臨床依據。- 公司正在開展多格列艾汀上市後真實世界研究（BLOOM），在全國80家中心納入2000例2型糖尿病患者，目前已完成1000余例患者的1年隨訪。在真實世界環境中，BLOOM研究進一步證明了多格列艾汀的廣泛適用性和安全性。在臨床用藥中，接受多格列艾汀治療的患者往往存在多種合並症，包括各種心血管和腎臟疾病等，並且正在接受多種伴隨藥物治療。除二甲雙胍外，超過60%的患者在使用多格列艾汀的同時，還聯合使用了SGLT-2抑制劑、胰島素、GLP-1受體激動劑或DPP-4抑制劑等其它降糖藥。無論是單藥治療還是聯合用藥，多格列艾汀普遍表現出良好的耐受性，安全性特徵也與先前的臨床研究資料保持一致。- 在2025年美國糖尿病協會（ADA）科學年會上，公司公佈了多格列艾汀的新研究資料，進一步闡明其作為疾病修飾療法的作用機制，關於多格列艾汀作為GKA藥物的新作用機制的相關成果已發表於《糖尿病》（Diabetes）雜誌上。研發管線與未來展望- 公司已在中國香港提交多格列艾汀75mg（商品名：華領片TM，MYHOMSIS(R)）的註冊申請，旨在擴大在大中華區和東南亞的業務版圖。- 公司正在通過開發二甲雙胍和多格列艾汀的固定複方製劑拓展產品管線，用於服用高劑量二甲雙胍（>每日1500mg）仍無法控制血糖的患者，此前的DAWN臨床研究顯示，多格列艾汀聯合二甲雙胍用藥可使患者的糖化血紅蛋白（HbA1c）降低超過1%，餐後血糖降低超過5mmol/L，低血糖發生率僅為0.8%。該血糖控制水準表明，多格列艾汀-二甲雙胍固定劑量複方製劑作為口服降糖藥具有強大的潛在需求。2025年8月，公司已完成IND前資料提交，預計於2026 年初啟動生物等效性（BE）研究。- 通過收集真實世界證據以及在動物模型中開展概念驗證研究，公司正在推進多格列艾汀與GLP-1受體激動劑、DPP-4製劑和SGLT-2抑制劑的聯合用藥。多格列艾汀與這些藥物之間的協同作用有望將其適應症擴展到肥胖症、代謝相關脂肪性肝炎（MASH）等其它代謝紊亂疾病領域。- 公司將繼續加強與國際領先的研究機構的合作。由華領醫藥支持的一項研究者發起的I 期臨床研究正在賓夕法尼亞大學進行，旨在評估多格列艾汀在囊性纖維化相關糖尿病（CFRD）患者中的療效和安全性，該試驗已獲得美國食品藥品監督管理局（FDA）的批准。- 公司將繼續致力於開發糖尿病預防、代謝紊亂相關神經退行性疾病領域的治療機遇，最終找到一種新的方法來延長人類的健康壽命。- 公司將繼續投資於數字技術平台，以在各個職能部門之間創造協同效應，並利用人工智慧技術提升品牌機遇。- 公司將繼續自主推進多格列艾汀和第二代GKA的研發，並與學術和戰略合作夥伴共同開展相關工作。公司正在推進多格列艾汀在香港的註冊，並繼續在東南亞和"一帶一路"國家尋求合作夥伴。基於美國I期單劑量遞增研究的初步成功，公司計劃於2025年底或2026年初啟動多劑量遞增I期研究，從而繼續推動第二代GKA在全球市場的業務發展。財務摘要截至2025年6月30日- 公司銀行結餘及現金約人民幣10.228億元- 總營收約2.174 億元，同比增長112%，华堂宁(R)銷量達176.4萬盒，同比增長108%- 毛利約1.178億元，同比增長147%，毛利率約54.2%，同比增長7.7個百分點- 其他收入約12.546億元，其中拜耳一次性遞延收入為12.435億元- 總開支約1.871億元，其中研發開支約6580萬元- 稅前利潤約11.839億元，同比增長932%前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（"本公司"）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖感測器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關資訊的，特別是標識或要求，應遵循中國監管機構批准的相關檔。另外，相關資訊不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 2025年8月，北京--首程控股有限公司（0697.HK，以下簡稱「首程控股」）、北京首程機器人科技產業有限公司（以下簡稱「首程機器人」）、阿爾特汽車技術股份有限公司（300825.SZ，以下簡稱「阿爾特」）、北京阿爾瑞特智能機器人科技有限公司（以下簡稱「阿爾瑞特」）正式簽署戰略合作框架協議。四方將充分發揮各自優勢，圍繞機器人產業的技術創新、應用落地、產業鏈協同與人才培養，展開全方位合作，推動「機器人+汽車」應用新業態加速發展。一、產業背景：機器人進入應用落地加速期當前，全球機器人產業正處於高速發展階段，國家戰略和政策密集出台。8月26日，國務院正式發佈《國務院關於深入實施「人工智能+」行動的意見》（國發〔2025〕11號），明確提出要推動人工智能與經濟社會各行業各領域的廣泛深度融合，加快形成人機協同、跨界融合、共創分享的智慧經濟和智慧社會新形態。在這一國家戰略指引下，機器人產業正從「技術突破」邁向「應用落地」。汽車與機器人作為兩個高度契合的產業，正逐漸呈現跨界融合趨勢。此次首程控股與阿爾特集團的合作，將在政策東風與市場需求的雙重驅動下，為機器人在研發、製造、交通和出行服務等關鍵環節的應用注入新動能。阿爾特是中國汽車設計領域的領軍企業，也是A股市場唯一的獨立汽車設計上市公司，具備整車研發設計與核心零部件製造的全流程服務能力，並踐行「技術+供應鏈」的國際化戰略。據公開資訊，公司累計服務超過80家客戶，參與開發近500款車型，客戶涵蓋一汽、東風、北汽、吉利、新勢力品牌與合資企業等主機廠類型。這意味著阿爾特在汽車產業鏈中擁有深厚的主機廠資源與交付能力。與此同時，阿爾特通過控股子公司--北京阿爾瑞特智能機器人科技有限公司，已正式開闢機器人新賽道。阿爾瑞特致力於打造一體化研發設計與仿真訓練平台，能夠為多場景機器人開發提供從仿真、測試到優化的全流程支撐；目前已啟動輪式機器人、水下機器人、鑽井機器人和寵物洗護機器人等多個研發項目，體現了其跨場景研發和產業協同的潛力。阿爾瑞特的加入，使本次合作不僅侷限於傳統汽車設計層面的協作，更在機器人研發、仿真與汽車產業化融合方面提供了重要支撐。與阿爾特及阿爾瑞特的合作，將幫助首程把機器人技術深度嵌入汽車產業鏈的核心環節，如整車製造、智能裝配與產線測試，使機器人真正進入產線、加速產業應用。這一戰略合作不只是一種技術對接，更是借助阿爾特在主機廠客戶群體中的資源網絡，將機器人場景從「隔壁展示」一步推向「生產車間」，連接研發驗證與規模化交付的關鍵路徑。二、合作重點：研發突破與應用落地並舉在國務院「人工智能+」行動政策引領下，四方將立足「技術研發-產業應用-生態共建」全鏈條，協同推進產業創新，重點在以下方向展開合作，助力機器人與汽車深度融合：（一）技術創新與聯合研發四方將聯合建設機器人一體化研發與仿真平台，借鑒汽車行業的完整研發體系，重點在運動控制、結構優化、車規級零部件和規模化製造等關鍵環節實現突破。同時，依託 NVIDIA Isaac/Omniverse 技術，共同打造一體化仿真訓練平台，不僅支援機器人在汽車研發、製造和測試中的應用模擬，還可開展智能駕駛車輛與物流機器人協同作業等跨場景模擬。雙方還將建立數據與成果共享機制：首程控股提供來自交通、出行等運營環節的數據資源，阿爾特輸出汽車工程和機器人研發經驗，形成從仿真-研發-驗證-產線應用的完整閉環。（二）優先採購與協同機制在研發設計、仿真訓練、整機和零部件供應等環節，四方將實行優先採購機制，在同等條件下優先選擇協議方為合作夥伴。首程控股與首程機器人重點提供產品推廣、代理及配套服務；阿爾特與阿爾瑞特聚焦於技術研發、工程化驗證和客製化整機開發。各方將協同推進機器人本體二次開發，確保機器人產品在汽車生產線、智能裝配和產線檢測等場景下實現最佳適配。通過分工協作，形成產品供給-技術創新-應用反饋的互補格局，加快成果轉化，提升商業化效率。（三）人才培養依託首程、阿爾特及其合作夥伴的科研與產業平台，四方將聯合開展技術攻關、仿真訓練與應用試點，為科研人員和工程師提供跨行業、跨場景的實踐環境。同時，定期舉辦技術研討會和產業論壇，邀請行業專家和上下游企業參與，建立聯合人才培養機制，打造一批兼具汽車工程背景與機器人產業化實踐經驗的青年科研人才，夯實長期發展的人才基礎。（四）拓寬發展空間四方將深度對接國家「人工智能+」與機器人產業發展戰略，重點推動「機器人+汽車」在研發、製造、測試和出行服務環節的規模化應用。在此基礎上，合作還將逐步延展至智慧交通、智能製造、醫療健康、教育、公共服務等更廣闊的領域，涵蓋機器人及核心零部件的設計、研發、生產、測試和商業化服務。同時，結合資本與產業的聯動，推動產業鏈上下游協同升級，最終形成從研發驗證到規模化應用的全鏈條閉環，打造具有示範效應的「機器人+汽車」應用矩陣，實現互利共贏和長期價值創造。三、戰略意義：打造機器人應用新標杆機器人產業的最大價值在於應用落地，而「機器人+汽車」正是最具潛力和爆發力的應用方向之一。從整車研發到智能製造，從交通調度到智慧出行，機器人將在汽車全產業鏈環節展現巨大價值。首程控股憑藉資本平台、生態資源與產業基金優勢，已投資宇樹科技、銀河通用、松延動力、星海圖、加速進化等國內頭部企業，具備前沿技術的整合能力；首程機器人則與上百家上下游優質企業建立合作，成為國內鏈接資源最全面的平台之一。阿爾特與阿爾瑞特則將汽車領域成熟的工程體系遷移至機器人研發與產業化。雙方優勢疊加，構建起「研發-迭代-應用-規模化」的完整路徑。此次攜手阿爾特，將進一步把首程的場景資源與產業生態，與阿爾特在整車研發、工程化能力與產業化經驗深度結合。未來1-2年，合作將聚焦「機器人+汽車」的深度融合，率先在汽車研發、生產製造、智慧交通與出行服務等環節實現規模化應用示範，推動機器人從實驗室走向產業化、規模化，加速形成具備示範效應的「機器人+汽車」應用矩陣。與此同時，合作也將放眼國際市場，推動中國方案走向全球，培育新質生產力，為股東創造長期價值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - FWD Group Holdings Limited (“FWD Group” or “FWD”) today announced its interim results for the six months ended 30 June 2025.- New business sales were up 38 per cent to US$1.246 billion compared to 2024 on an annualised premium equivalent (APE) basis. New business contractual service margin (CSM) of US$794 million, with year-on-year growth of 34 per cent.- Operating profit after tax was up 9 per cent to US$251 million with continued positive contributions from each of the company’s four geographic reporting segments: Hong Kong SAR & Macau SAR; Thailand & Cambodia; Japan; and Emerging Markets.- Net profit of US$47 million is a record interim result under IFRS 17.- Further improved financial flexibility with an upgrade to FWD Group's ratings - with its notional insurer financial strength rating now A2 - as announced by Moody's in July 2025. Maintained a strong capital position with a 283 per cent solvency ratio* and net underlying free surplus generation that more than doubled to US$417 million. Dividends of over US$500 million were received from the geographic reporting segments. - Comprehensive tangible equity up 8 per cent to US$8.15 billion, and Group embedded value up 8 per cent to US$6.38 billion, reflecting the value created for shareholders during the first half of 2025. The company subsequently completed its IPO - which raised HK$3,611 million (approximately US$466 million) in gross proceeds – and began trading on 7 July 2025 under the stock code 1828 on the Hong Kong Stock Exchange.- Completed the build-out of a high-net-worth (HNW) hub in Asia operating out of three jurisdictions – Hong Kong SAR, Singapore and Bermuda – serving the global high-end insurance market with diversified asset allocation, wealth management and legacy planning. A new FWD Private lounge located in a prime commercial district in Hong Kong is now fully operational.Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “We’re delighted to report record interim results under IFRS 17 in our first earnings as a publicly listed company. The outstanding growth in new business CSM demonstrates our ability to execute our customer-led strategy successfully across Asia in a sustainable and profitable way.“We intend to use the net proceeds of our recent IPO to further enhance our capital position and financial flexibility, which may involve reducing debt, in support of further growth and reach with customers, digital capabilities and channels,” added Huynh Thanh Phong.In Hong Kong SAR & Macau SAR, outstanding growth was posted in new business sales and new business CSM, reflecting ongoing broad-based demand from both local and Mainland Chinese visitor customers and the full activation of the FWD Private HNW business. The company continues to focus on its multi-channel distribution strategy alongside product innovation – such as its indexed universal life offering developed following recent regulatory guidance, as well as new cross-border Greater Bay Area medical services for eligible customers.The Thailand & Cambodia reporting segment new business indicators were partly impacted by the exit from underwriting new business in the Thailand corporate care segment in 2024. The business remains well positioned in Thailand to meet demand for protection, medical and pension products from an aging population. Its exclusive bancassurance partnership with Siam Commercial Bank maintained its number one market position. Similarly, the company’s agents and advisors retained a number two position in the annual Million Dollar Round Table (MDRT) rankings released in July 2025. The MDRT is a global independent association recognised as a standard of excellence in the life insurance and financial services industries.In Japan, the business reported solid new business results from its individual protection focused portfolio. The introduction of its first savings offering in July – a Japanese yen single premium annuity product – marked the company’s entry into the savings and retirement needs market.  The Emerging Markets segment reported strong new business sales growth, despite industry headwinds and economic uncertainty in several markets. In Indonesia, BRI Life – a joint venture where FWD Group holds a strategic 44 per cent investment and collaborates with Bank BRI – was number one in bancassurance by new business sales. In the Philippines and Vietnam, the company’s agents and advisors ranked number two in the latest annual MDRT rankings.  Six months ended/as at 31 Dec or 30 Jun^   US$ millions, except for percentages2025  2024Growth(year on year CER basis)          Profitability       Operating profit after tax2512239%  Net profit/(loss)473nm  CSM balance5,9965,17411%  Growth     New business sales (APE)1,24687638%  New business CSM79457334%  Value of new business50640421%  Customer indicators     Purchase customer emotion – good or great92%92%n/a  Claims customer advocacy – net promoter score6364n/a  Risk & Capital     Net underlying free surplus generation417193115%  Group local capital summation method coverratio*283% 260%n/a  Value     Group embedded value6,3805,5698%  Comprehensive tangible equity8,1507,1628%  Return on tangible equity17%15%n/a About FWD GroupFWD Group (1828.HK) is a pan-Asian life and health insurance business that serves approximately 34 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the main board of the Hong Kong Stock Exchange under the stock code 1828. For more information, please visit www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings Limited^ The results are for the six months ended 30 June 2025 and are compared to the same period in 2024. CSM balance, Group LCSM cover ratio, group embedded value, comprehensive tangible equity and return on equity 2024 values are December 2024 balances/ratios and growth rates are shown accordingly. Growth rates are represented on a constant exchange rate (CER) basis. Except for operating profit/(loss) after tax (non-IFRS measure), net profit/(loss), CSM, and comprehensive tangible equity, all other numbers are unaudited. Operating profit after tax and net profit after tax represent the amounts attributable to equity holders of the company and are presented net of non-controlling interests. New business sales are calculated on an annualised premium equivalent (APE) basis, based on 100 percent annualised first year premiums and 10 percent single premiums. Return on tangible equity is calculated as operating profit after tax, divided by the average of the balances of tangible equity as of the beginning and end of such period. Tangible equity is calculated as adjusted total equity attributable to shareholders of the company, minus the intangible assets net of non-controlling interests.*Prescribed capital requirement (PCR) basis Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 天能動力國際有限公司(「公司」，連同其附屬公司，統稱「集團或天能」）（股份代號：00819.HK)公布截至2025年6月30日止六個月（「報告期內」）之中期業績。2025年上半年，天能堅持戰略引領、改革破局的總體思路，統籌推進實業、科技、資本三輪驅動戰略。在鞏固鉛蓄電池業務核心競爭力的同時，加速海外市場開拓，推動新能源電池業務從積累轉向釋放，深化電池循環體系的縱深建設，驅動業務全景化、可持續發展。報告期內，集團實施聚焦主業、主動收縮貿易業務戰略，實現制造業營業收入約人民幣211.68億元，較去年同期基本持平，占整體營業收入比例提升至約87.5%；實現貿易業務營業收入約人民幣30.24億元，較去年同期下降約89.47%，占整體營業收入比例下降至約12.50%。製造業中，高端環保電池業務穩築基本盤，為戰略轉型提供堅實的財務後盾。新興業務高速增長，其中，鋰離子電池業務取得營業收入約5.01億元，較去年同期躍升174.58%。報告期內，集團實現毛利額約人民幣25.37億元，較去年同期基本持平；經營現金流釋放躍升，由去年同期約人民幣1.62億元淨現金流出轉變至約人民幣8.91億元淨現金流入。綜上，2025年上半年，在複雜外部環境下，天能展現出強大經營韌性、發展動能和戰略執行力。國際化進程加速 海外市場拓展成果顯著國際化布局是集團提升全球競爭力、實現增量跨越的重要戰略支點。2025年上半年，海外業務呈現突破性增長，市場反饋持續向好，實現營業收入約人民幣2.26億元，較去年同期增長約75.39%。報告期內，集團以當地需求為導向，結合海內外產業資源加速國際市場開拓，於泰國、越南、土耳其等地配置本地運營團隊，發展數十家授權經銷商，銷售網絡覆蓋亞太、歐美、中東非各地區主要國家。越南生產基地建設有序推進，組裝基地產能全面釋放，為區域深耕奠定基礎。針對性開發本地化產品，滿足差異化需求；重點建設本地化渠道與運營團隊；同步推進“服務出海”戰略，系統性構建本地化服務標準體系。優化全球供應鏈，釋放增長動能。主業穩中見韌 蓄勢動能長青 ​報告期內，集團在複雜外部環境與產業結構再平衡的背景下，堅持「穩中求進，以進促穩」的經營節奏。高端環保電池業務表現堅實，上半年取得營業收入約人民幣182.92億元，為集團穩健續航持續注入動力。高端環保電池是集團基於研發與工藝創新打造的密封型免維護鉛蓄電池，深度適配電動輕型車市場需求，憑借其綜合成本及性能優勢，亦廣泛應用於備用電源、汽車電池與電動特種工業動力電池等領域。集團秉持核心業務優勢，深化智能制造升級、精進運營管理體系、鞏固銷售渠道網絡，驅動產品質量持續提高與綜合市場競爭力不斷增強，強化鉛蓄電池業務在複雜市場環境下的發展韌性。報告期內，集團通過智能制造體系應用與設備技術改造升級，有效提升制造效能與供應鏈保障能力，成本管控成效逐步顯現；依托電池技術迭代驅動產品性能升級，圍繞電動輕型車、數據中心、汽車起動啟停與工業動力等重點場景，形成差異化產品矩陣；驅動以用戶價值為核心的服務體系升級，深度整合傳統經銷網絡與創新數字生態。深化多元技術路線 加快業務增長新動能2025年上半年，集團錨定新能源業務發展方向，圍繞鋰離子電池、固態電池、氫燃料電池、鈉離子電池等多技術路徑，系統推進研發攻關、智能制造與場景拓展，加快培育業務增長新動能。集團鋰離子電池主要聚焦儲能與低速動力等領域。報告期內，集團儲能與低速動力業務實現量的躍升與質的改善，工業電池及駐車空調電池等細分市場增量空間得以拓展，產能利用率明顯提升，整體營收顯著增長，經營質效明顯改善，取得營業收入約5.01億元，較去年同期增長約174.58%。集團固態電池研發取得階段性進展，重點突破高比能、長循環及高倍率三大方向，與頭部兩輪車企業建立戰略合作關系，並在低空飛行器領域與相關企業推進解決方案驗證。集團在氫燃料電池持續投入，擁有全鏈條研發體系和專家團隊，產品性能先進，在兩輪車、公交、重卡及特種機械等場景推進示範驗證，並與上下遊合作夥伴共同構建應用生態。集團同步推進鈉離子電池技術與應用布局，報告期內圍繞汽車起動啟停與儲能等應用場景開展低溫與循環壽命等關鍵指標驗證，保持穩健的產業化節奏。通過多技術路徑的協同，遵循「技術攻堅—場景驗證—方案化交付」的推進節奏，集團新能源電池業務增長動因正由點式驗證向鏈條釋放有序過渡，業務動能得到紮實支撐。夯實循環體系 強化產業協同新動能集團專注於電池產業，系統構建覆蓋生產、回收、再利用的全生命周期產業鏈，形成鉛蓄電池和鋰離子電池雙軌循環產業體系，實現資源高效再生利用。報告期內，集團可循環產業實現對外營業收入約人民幣18.00億元，較去年同期增長約15.82%。作為國內循環產業的領先企業，集團著眼於構建兼具前端觸達能力與後端處理效率的高效回收網絡，以規模化的處置能力和業務協同優勢推動廢舊電池資源有效利用，關鍵材料回收率居於行業前列。報告期內，集團持續貫通回收、處置與再利用全流程，提升鉛蓄電池回收渠道整合力與運營精度；強化鋰離子電池回收差異化路徑布局，深化核心區域與重點場景資源聯動。集團通過深挖技術潛能與優化系統表現，逐步釋放循環體系的規模優勢與經濟價值，為產業注入持久動能。展望未來，天能將以技術革新驅動產業升級，以數智化賦能運營增效，以生態協同重塑價值鏈體系，以全球化布局開拓增量空間，鞏固鉛蓄電池核心主業優勢，加快推進鋰離子電池、固態電池等新能源電池的研發、應用與市場開拓，強化電池回收與資源再生能力，提升產業鏈一體化水平與協同效率。天能將同步加速海外市場布局與本地化經營能力建設，向制造與服務體系延伸，構建發展為具備長期競爭力和全球視野的新能源電池產業格局企業。天能將持續推動企業價值與社會價值深度融合、共同成長，打造可持續、高質量增長的創新範式。關於天能動力國際有限公司天能動力國際有限公司及其附屬公司創立於一九八六年，總部設於中國，憑借完善的制造體系與技術優勢，發展成為新能源電池行業領先企業及輕型電動車電池領域龍頭企業，二零零七年於香港聯合交易所有限公司主板上市（股份代號：00819.HK）。曆經近四十載發展，集團以鉛蓄電池為核心主業，深耕電動輕型車動力電池市場，並拓展至備用電源、汽車電池與工業動力電池等多元領域。集團為全面布局未來新能源生態，在堅守主業優勢的基礎上，積極推進鋰離子電池、固態電池、氫燃料電池及鈉離子電池的研發、生產與銷售，以多技術路線產品矩陣覆蓋多元新能源應用場景，並同步構建循環經濟產業鏈，依托廢舊鉛蓄電池與廢舊鋰離子電池循環利用業務，推動資源高效再生。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Tianneng Power International Limited (the “Company”, together with its subsidiaries, collectively referred to as the “Group” or “Tianneng”), (Stock Code: 00819.HK) releases its interim report for the six-month period ended 30 June 2025.In the first half of 2025, adhering to the Group’s vision of Strategic Guidance and Reformation Breakthrough, Tianneng coordinated the three-wheeled strategy of Industry, Technology, and Capital. While solidifying the core competency of the lead-acid battery business, the Group also accelerated the expansion of overseas markets, released the Group’s built-up potential in new-energy battery, deepened the vertical construction of the battery recycle system, and drove the diversification of products and sustainability.Within the reporting period, the Group made a strategic pivot to reduce the trade business, achieved RMB 21.168 billion in revenue for the manufacturing business, which was stable compared to the same period in 2024, accounting for approximately 87.5% of the total revenue within the sector. In terms of the trade business, the Group realized an overall revenue of RMB 30.24 billion, which represented an 89.47% decrease from the same period of 2024. Within The manufacturing sector, the high-end eco-friendly battery business remained stable, providing a resilient financial support for the Group. The emerging businesses experienced significant growth, among which the Li-ion battery business achieved a revenue of RMB 0.501 billion, representing a 174.58% growth from the same period of 2024. Within the reporting period, the Group achieved a gross profit of RMB 2.537 billion, which is stable compared to the same period of 2024. In terms of operating cash flow, the Group achieved RMB 0.891 billion of net inflow, compared to a net outflow of RMB 0.162 billion in the same period of last year. Overall, in the first half of 2025, Tianneng demonstrated strong resilience, developmental momentum, and strategic commitment in a complex external environment.Internationalisation Accelerated, Overseas Expansion Bore FruitsInternational expansion is a vital fulcrum of the Group in strengthening global competitiveness and achieving incremental leaps. In the first half of 2025, the overseas business experienced remarkable growth with continuous positive feedback, achieving a revenue of RMB 0.226 billion, representing a 75.39% growth from the same period of 2024.Within the reporting period, guided by local demands, the Group accelerated its overseas expansion with global industrial resources, and set up operational teams in countries such as Thailand, Vietnam, and Turkey while developing a sales network in major areas including the Asia-Pacific, Europe, North America, the Middle-East and Africa. In addition, the Group’s production base in Vietnam is being constructed in an orderly manner while the capacity of the assembly base is robustly released, laying the groundwork for future developments in the region. The Group has developed customised products based on specific local demands and emphasised building localised operational teams, while advancing its “Overseas Service” strategy, and systematically constructed localised standards. With these developments, the Group was able to optimise its global supply chain and release future growth potentials.Core Business Stable and Resilient, with Promising Growth MomentumWithin the reporting period, the Group pursued a path of “Stability and Growth Duality” under a complex external environment and industrial structure re-balancing. The high-end eco-friendly battery business demonstrated resilience, achieving a revenue of RMB 18.292 billion, providing the vital financial stability for the Group. The high-end eco-friendly batteries are sealed, maintenance-less lead-acid batteries built with the Group’s innovation in design and manufacturing, highly adapting to the demands of the light electric vehicle market, with their cost and performance superiority, are also widely utilised in various fields, including backup power supplies, automobile batteries, and special-purpose industrial power batteries.The Group solidified its competencies in the core business, upgraded its intelligent manufacturing capabilities, improved the operational management system, consolidated its sales network, drove product quality and comprehensive market competitiveness growth, and fortified the resilience of lead-acid batteries in a complex market environment. Within the reporting period, the Group was able to effectively upgrade its manufacturing efficiency and supply-chain resilience through utilising intelligent manufacturing systems and equipment technology upgrades, while demonstrating effective results in cost management. Through the evolution of battery technologies and product upgrades, the Group constructed a differentiated product matrix targeting major fields of usage such as light electric vehicles, data centres, automobile start-stop batteries, and industrial power batteries,driving a service system upgrade with user value at its core, and organically merged the traditional sales network with an innovative digital ecosystem.Solidifying the Diversity of Technological Road-maps and Accelerating New Business Growth In the first half of 2025, the Group committed to the development of new-energy businesses, including Li-ion batteries, solid-state batteries, hydrogen fuel cells, and sodium-ion batteries, and systematically drove innovative breakthroughs, intelligent manufacturing upgrades, user-scenario extensions, and fostered new business growth. The Group’s Li-ion batteries business mainly targets power storage and low-speed power. Within the reporting period, the Group’s power storage and low-speed power business achieved major improvements both in terms of quality and quantity. Specific markets, such as industrial batteries and automobile A/C batteries, also saw improvements in market volume. Overall, the capacity utilisation of the Group’s new-energy business was significantly enhanced, with remarkable improvements in operational efficiency and revenue, RMB 0.501 billion, a 174.58% increase from the same period of 2024.The Group’s solid-state battery also achieved intermittent success within the three dimensions of high energy density, cycle longevity, and high-rate performance. The Group also formed strategic collaborations with industry leaders in the two-wheeled vehicle market and carried out solution testing with partners targeting the low-altitude flying vehicle market. The Group continued its investment in hydrogen fuel-cells with a full-chain R&D system and an expert team, with advanced products, began testing in user-scenarios such as two-wheeled vehicles, public transportation, heavy trucks, and special-purpose machinery, and collaborated with upstream and downstream partners in constructing an application ecosystem. The Group also spearheaded the development and application of sodium-ion battery technology, and conducted experiments for key metrics such as low-temperature and cycle longevity testing for scenarios such as power storage and automobile start-stop battery in a steady manner. Through the multi-roadmap approach, and the “technology breakthrough - user scenario verification - solution delivery” process, the Group’s new-energy business growth is gradually and steadily shifting from individual verification to chain-release, firmly supporting the business momentum.Strengthening the Recycling System and Fortifying Industrial CollaborationThe battery industry is at the core of the Group’s business, which systematically constructed a full-life industry chain of manufacturing, recycling, and reusing, forming a two-railed industry system of lead-acid battery and Li-ion battery, achieving efficient recycling. Within the reporting period, the recycling business of the Group achieved a revenue of RMB 1.8 billion, a 15.82% increase compared to the same period of 2024.As a leader in the recycling industry in China, the Group is continuously building an effective recycling network with front-end reach and back-end efficiency, promoting the efficiency of waste battery recycling empowered by the collaborative effort of businesses at scale, and achieving a top-of-industry recycling ratio of crucial materials. Within the reporting period, the Group continued to enhance the granularity and precision of the recycling process from recycling, processing, and reusing, improve the differentiating system for Li-ion battery recycling, and improve the resource synergies at core regions and user scenarios. Through uninterrupted exploration of technological potential and system performance optimisation, the Group was able to gradually achieve scale advantage and economic value of the recycling system, injecting continuous momentum for the industry.Looking forward, Tianneng will drive industrial upgrades through technological innovation, empower efficient operation through digitisation, rebuild the value-chain system through ecological collaboration, and seek growth through internationalisation. The Group will solidify its competencies in the lead-acid market, accelerate the research, application, and market expansion process of new energy batteries such as Li-ion battery and solid-state battery. The Group will strengthen its capabilities in battery recycling, enhance the collaborative efficiency of industry-chain integration while expediting its expansion into overseas markets and optimising localised operation, from product to service, and develop into a new-energy battery company that is competitive with a global vision. Finally, the Group will promote the convergence between its company values and social values with a growth mindset and build a new paradigm of sustainable and high-quality growth.About Tianneng Power International LimitedTianneng Power International Limited and its subsidiaries (collectively referred to as “Tianneng” or the “Company”), founded in 1986 and headquartered in China, has developed into a leading enterprise in the new energy battery and the light electric vehicle battery industry with a comprehensive manufacturing system and technological advantage. Tianneng was listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 00819. HK) in 2007. After nearly four decades of development, Tianneng has established lead-acid batteries as its core business, focusing on the market of motive batteries for light electric vehicles, while expanding its product in automotive start-stop systems, backup power for communication base stations and other diversified scenarios. The Company is also advancing the R&D, production and sales of lithium-ion batteries, hydrogen fuel cells, sodium-ion batteries and solid-state batteries, offering multi-technology battery solutions for special industrial vehicles, energy storage systems and other applications. Additionally, Tianneng strengthens its recycling economy initiatives around its core operations. Through a dual-track system for lead and lithium recycling, the Company achieves efficient resource regeneration and reuse, building a comprehensive ecosystem for the new energy industry. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 領先的中國醫學運營服務供應商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2025年6月30日止（「報告期」）之中期業績。集團以「一橫一縱」為主要經營策略，橫向輸出精益運營體系，推進醫聯體多模式合作，縱向聚焦專科方向上的醫檢聯合創新，加速新技術新產品轉化及應用推廣，同時以AI賦能醫聯體整體解決方案，推動AI在醫療場景的實際應用，持續強化臨床賦能價值，呈現強大的經營韌性。2025年上半年，受集採、醫保控費及行業競爭加劇等多方面因素影響，導致集團短期業績未達預期，然而集團始終堅持產品創新和模式創新，並進一步完善企業經營管理的機制和流程，堅持精益運營，整體經營取得明顯成效。報告期內，集團毛利率約為34.0%，較2024年度整體毛利率提升約4.4%；虧損淨額人民幣55.4百萬元，較上年同期減少56.1%，明顯收窄。此外，醫聯體共建業務板塊持續為集團第一大業務板塊，錄得收益人民幣180.3百萬元，佔總收益的57.6%，較上年同期提升約9.6%，在深度服務賦能醫聯體客戶方面成效顯著，為集團長期高質量發展奠定基礎。報告期內，集團診斷檢測服務錄得收益人民幣313.2百萬元。一橫一縱策略穩步實施，院企合作成效明顯「一橫」——輸出精益運營體系，深化醫聯體多模式合作雲康一直致力於發展「以專業化為基礎、標準化為核心、數智化為手段、協同化為目標」的醫聯體共建創新服務模式。報告期內，集團已為近450家醫聯體客戶提供不同臨床需求的多場景解決方案，包括AI+醫聯體數智化解決方案、醫學實驗室整體合作、區域╱病理中心解決方案、精準醫學中心解決方案、專科聯盟建設解決方案等多模式合作。透過發揮雲康優勢，協助各級醫療機構提升服務能力、外拓服務範圍，構建分級協同的醫療服務體系，促進區域分級診療發展。報告期內，雲康持續與頭部引領型醫院、各地區市縣級醫院展開深度合作，在市場競爭形勢日趨嚴峻的情況下，醫聯體共建業務板塊仍保持穩健發展，競爭優勢進一步鞏固。「一纵」——醫檢聯合創新平台打造科研創新強引擎集團始終聚焦「臨床需求」，不斷加強院企合作，首創性打造「醫檢聯合創新平台」，助力集團業務開拓及提升產品競爭力。報告期內，集團已與全國數十家頂級醫療機構開展醫檢聯合創新合作，累計成功開發出數十項針對呼吸道感染、中樞神經系統感染、泌尿系統感染、婦科感染、結核感染等多領域的不同感染症候群檢測產品，以及個性化用藥基因檢測產品，創新產品累計服務客戶近300家，檢測收益持續增長。報告期內，雲康與廣東省人民醫院先後上市呼吸道感染、中樞神經感染、侵襲性真菌感染等系列新panel產品，成功構建國內院企科研創新轉化標準化孵育模式和「1+N」醫檢協同網絡，此外，雙方在科研創新過程中，積累了豐富的臨床經驗，在數十位國內臨床、檢驗等多領域專家學者的積極參與和持續推動下，形成了《tNGS臨床規範化應用專家共識》，並於報告期內在國內檢驗頂級期刊《中華檢驗醫學雜誌》發佈。報告期內，雲康亦與國內頂尖醫院廣州醫科大學附屬第一醫院緊密合作，成功開發泌尿tNGS產品，推動尿路感染精準診療的臨床實踐。同時，雲康與暨南大學附屬第一醫院聯合打造「校院企聯合創新平台」，孵化和運營「精神疾病藥物基因檢測創新項目」，並成功開發出抗抑鬱藥物基因檢測、抗焦慮及鎮靜安眠藥物基因檢測產品。AI賦能醫聯體多模式解決方案，提質增效深化客戶服務報告期內，雲康全面接入DeepSeek，實現集團數字化平台部署。雲康以「AI+」與「精準診斷」為核心理念，將人工智能技術廣泛應用於旗下醫學實驗室的多技術平台。以AI技術與雲康病理診斷平台的深度融合為例，雲康病理檢測流程被極大壓縮，單切片AI診斷效率持續優化，實現智能、效率、質量三重提升。此外，透過部署智能化功能應用，雲康已實現智能在線客服、結果與報告高效審核等功能，全面優化醫檢服務的流程，提升客戶服務體驗和滿意度。在院企聯合研發新技術新產品過程中，借助AI大模型強大的數據分析、模型構建和智能預測能力，雲康AI技術從生信分析、報告解讀、疾病風險評估、創新產品研發轉化等多方面賦能產品創新研發，加速產品落地臨床。值得一提的是，雲康攜手潤達醫療、華為共同開發的醫療大模型「智雲」已重磅發佈，覆蓋了診前、診中、診後的全流程場景，將為臨床醫療服務全流程提供更加高效、便捷的支持和體驗。同時，雲康與潤達醫療簽署戰略合作協議，以強化「AI+IVD+醫療服務」在產業生態鏈之間的深度合作，並共同推動人工智能大模型在醫療端的發展與應用，為客戶提供數智化的醫療解決方案。未來，「智雲」醫療大模型將在雲康合作醫療機構中試點應用，並逐步推廣至全國，為醫聯體建設運營提質增效。未來展望2025年是「十四五」規劃的收官之年，國家推動優質醫療資源加快擴容下沉，促進區域佈局更加均衡，同時不斷加快醫聯體建設，推動其由「搭框架」向「高質量運營」升級。臨床治療亦正從「廣譜治療」邁向「精準化治療」新階段，行業增長潛力持續釋放。同時，AI技術持續賦能分級診療，行業將迎來發展新機遇。展望未來，雲康將繼續緊跟行業發展脈搏，以國家政策為導向，不斷強化臨床賦能價值，持續探索「產品創新+模式創新」雙輪模式，加速業務開拓，深度賦能醫學檢測服務，惠及更多居民。雲康集團有限公司（股份代號：2325）雲康集團是中國領先的醫學運營服務提供商，早於2008年雲康便開始面向各級醫療機構提供標準化的醫療診斷服務，透過利用自身專業的診斷能力以及覆蓋全國的醫聯體服務網絡，逐漸發展成為醫學運營服務的領先平台。雲康也是中國領先的醫聯體診斷服務供應商，提供涵蓋醫聯體診斷及診斷外包的全方位醫療健康服務。雲康向中國醫聯體內的合作醫院提供診斷檢測服務，透過現場診斷中心協助其提升臨床診斷能力。迄今為止，雲康已成功為來自全國近450家現場診斷中心提供專業服務，截至2025年6月30日，雲康合作的醫院分佈於中國31個省市。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"). The Group adopted “one horizontal, one vertical” as its core business strategy: horizontally, it extended a lean management system to advance multi-mode collaboration among medical institution alliances; vertically, it focused on specialty-specific innovation in medical diagnostics to fast-track the translation and implementation of new technologies and products. Meanwhile, the Group leveraged AI to enhance the comprehensive solutions for medical institution alliances, promoted the practical application of AI in healthcare scenarios, and continuously strengthened the value of empowering clinical practices, demonstrating strong operational resilience.In the first half of 2025, due to multiple factors, including the centralized drug-procurement program, cost controls of medical insurance, and fierce market competition, the Group’s short-term results did not meet expectations. However, the Group remained committed to product and business model innovation, and further refined the mechanisms and processes of its operational management. By adhering to lean operations, the overall performance has achieved significant improvements. During the Reporting Period, the Group’s gross profit margin reached approximately 34.0%, representing an improvement of approximately 4.4% over the overall gross profit margin for 2024. The net loss amounted to RMB55.4 million, a significant decrease of 56.1% compared to the same period last year. The joint construction business remained the Group’s largest business segment, which recorded the revenue of RMB180.3 million, accounting for 57.6% of the total revenue, increased by approximately 9.6% as compared with the same period last year, achieving significant outcomes in empowering medical alliance clients through in-depth services, paving the way for the Group’s long-term high-quality growth. During the Reporting Period, the Group’s diagnostic testing services recorded revenue of RMB313.2 millionSteadily implementing “one horizontal, one vertical” strategy, with notable achievements in hospital-enterprise partnerships“One horizontal” ——Extending lean management system to deepen diverse forms of collaboration within medical institution alliancesYunkang has been committed to developing an innovative service mode for the joint construction of medical institution alliances featuring “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. During the Reporting Period, the Group provided nearly 450 alliance clients with multi-scenario solutions tailored to different clinical needs, including AI+ digital intelligence solutions for medical institution alliances, comprehensive collaborations with medical laboratories, solutions for regional/pathology centers and precision medicine center, and specialty-based solutions for alliance development, among other multi-model collaboration services. By leveraging Yunkang’s strengths, the Group assisted healthcare institutions at all levels in enhancing service capabilities and expanding service coverage, established a hierarchical and coordinated healthcare service system, and promoted the development of regional hierarchical diagnosis and treatment services.During the Reporting Period, despite increasingly fierce market competition, the Group maintained solid growth in the joint construction business through continuous deep collaboration with leading hospitals and municipal and county-level hospitals, further consolidating its competitive advantage.“One vertical” ——Joint innovation platform for diagnostic testing serves as strong driver for R&DThe Group has always focused on “clinical needs”, continuously strengthening hospital-enterprise collaboration and pioneering the establishment of a joint innovation platform for diagnostic testing, driving business expansion and product competitiveness. During the Reporting Period, the Group forged joint diagnostic innovation partnerships with dozens of top-tier medical institutions nationwide, delivering a portfolio of testing products addressing multiple infectious syndromes, including respiratory tract infections, central nervous system infections, urinary tract infections, gynecological infections, and tuberculosis, as well as genetic testing products for personalized medication. Collectively, these innovative products have served nearly 300 clients across the country, and achieved sustained growth in testing revenue.During the Reporting Period, Yunkang and Guangdong Provincial People’s Hospital successively launched a series of new panel products covering respiratory tract infections, central nervous system infections, and invasive fungal infections, successfully creating a standardized incubation model for domestic hospital-enterprise research innovation and translation, as well as a “1+N” medical inspection collaboration network. Moreover, throughout the process of scientific and technological innovation, both parties have gained rich clinical experience. With the active involvement and sustained efforts of dozens of domestic diagnostic experts and scholars, they formulated the Expert Consensus on the Application of tNGS for Clinical Standardization, which was published during the Reporting Period in Chinese Journal of Laboratory Medicine, a leading journal in China’s diagnostic field. During the Reporting Period, Yunkang also maintained close collaboration with the First Affiliated Hospital of Guangzhou Medical University, one of China’s top-tier hospitals, and successfully developed a urinary tNGS product, advancing the clinical practice of precision diagnosis and treatment for urinary tract infections. Simultaneously, Yunkang partnered with the First Affiliated Hospital of Jinan University to establish a “university-hospital-enterprise joint innovation platform” and incubated and operated the “innovation project of psychiatric drug genetic testing”, which has successfully yielded genetic testing products for antidepressants, anti-anxiety drugs, and sedative-hypnotics.AI empowers multi-modal solutions for medical institution alliances, improving quality and efficiency to deepen client services  During the Reporting Period, Yunkang fully employed DeepSeek and achieved digital deployment across its platforms. Centered on the core concepts of “AI+” and “precision diagnostics”, Yunkang extensively applied artificial intelligence technology across the multi-technology platforms of its medical laboratories. Taking the in-depth integration of AI technology with Yunkang pathology diagnosis platform as an example, the per-slide efficiency of AI-empowered diagnostic was continuously optimized, achieving simultaneous improvements in intelligence, efficiency, and quality. Moreover, through the deployment of intelligent applications, Yunkang realized smart online customer services and the efficient review of results and reports, which fully streamlined diagnostic service processes and improved experience and satisfaction of its client services. In the process of jointly developing new technologies and products through hospital-enterprise R&D, Yunkang’s AI technology empowered product innovation and R&D across multiple aspects, including bioinformatics analysis, report interpretation, disease risk assessment, and development and translation of novel products, by leveraging the powerful data analysis, modeling, and predictive capabilities of large-scale AI models. This has accelerated the clinical implementation.Notably, Yunkang unveiled its medical AI model “ZhiYun” developed in collaboration with Runda Medical and Huawei, spanning the entire clinical workflow from pre-diagnosis to diagnosis and post-diagnosis. It will provide more efficient and convenient support and experience across all stages of clinical medical services. Meanwhile, Yunkang signed a strategic cooperation agreement with Runda Medical to strengthen in-depth collaboration across the industrial ecosystems in “AI + IVD + healthcare services”, jointly promoting the development and application of large-scale AI models in the medical field, and providing clients with digital-intelligence healthcare solutions. In the future, “ZhiYun”, the medical AI model, will be piloted in Yunkang’s healthcare partners and gradually rolled out nationwide, to improve quality and efficiency of medical institution alliance operations.Future prospects2025 marks the final lap for implementing the 14th Five-Year Plan. China has accelerated the capacity expansion of premium healthcare resources and their extension to lower-tier markets, resulting in a more balanced regional distribution. The country has also expedited the development of medical institution alliances and driven their upgrade from “framework building” to “high-quality operation”. Clinical treatment is also shifting from “broad-spectrum therapies” to “precision medicine”, with the growth potential of the industry continuing to be realized. At the same time, AI technology has continued to empower hierarchical diagnosis and treatment services, and the industry is embracing new growth opportunities.  Looking ahead, Yunkang will continue to keep pace with industry development trends and align with national policies, further strengthening the value of empowering clinical practices, and persistently exploring the “product innovation + business innovation” dual-pronged model to accelerate business development, deeply empower medical testing services, and benefit more residents.Yunkang Group Limited (Stock Code: 2325)Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to nearly 450 on-site diagnostic centers. As of June 30, 2025, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

SAN DIEGO, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - The YFQ-42A Collaborative Combat Aircraft, designed and developed by General Atomics Aeronautical Systems, Inc. (GA-ASI), is now conducting flight testing in coordination with the U.S. Air Force. This historic achievement continues the company's rapid creation of new, jet-powered uncrewed platforms chartered by the U.S. Air Force (USAF) to achieve air dominance while being designed for rapid production, in large quantities, at an affordable price."What a great moment for the U.S. Air Force and for GA-ASI," said GA-ASI President David R. Alexander. "It's been our collaboration that enabled us to build and fly the YFQ-42A in just over a year. It's an incredible achievement and I salute the Air Force for its vision and I salute our development team for delivering yet another historic first for our company."The YFQ-42A is GA-ASI's newest uncrewed jet, focused on air-to-air semi-autonomous operation and based on the genus-species concept pioneered on the XQ-67A Off-Board Sensing Station (OBSS). Using state-of-the-art, model-based digital engineering, GA-ASI was able to accelerate its schedule while optimizing air dominance capabilities. YFQ-42's autonomy core has been trained across more than five years of flight testing using GA-ASI's jet-powered MQ-20 Avenger®, an aircraft no other company has. The integrated capabilities of a stealthy, air-to-air-focused uncrewed jet, combined with a learned AI autonomy core, provide warfighters with a definitive advantage in the future fight.The GA-ASI program has focused on creating a high-rate production environment that enables USAF to reach its goal of producing more than 1,000 CCAs on an accelerated timeline. Ground testing for YFQ-42A began in May.USAF selected GA-ASI in April 2024 to build and fly a fully production-representative Collaborative Combat Aircraft (CCA). In March, USAF designated the aircraft the YFQ-42A, with the "Y" indicating a production-representative aircraft ("Y" will be dropped upon entering production), "F" signifying a fighter aircraft, and "Q" denoting an uncrewed aircraft.GA-ASI has developed more than two dozen different types of uncrewed aircraft and delivered more than 1,200 units to customers, building more than 100 aircraft per year at its 5 million-square-foot manufacturing facility in Poway, Calif. GA-ASI aircraft have amassed nearly 9 million total flight hours; more than 50 GA-ASI aircraft are aloft around the world every minute of every day.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging nearly 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc. registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - TechInnovation® 2025, Singapore’s preeminent platform for innovation and business transformation, returns for its 13th edition from 29–31 October 2025 at Sands Expo & Convention Centre, Level 3 Heliconia and Hibiscus Ballroom, Singapore. Organised by IPI Singapore, the three-day event will bring together over 40 expert speakers, more than 100 breakthrough technologies and curated programmes designed to accelerate real-world innovation and cross-border collaboration.Building on last year’s momentum, which brought together more than 100 exhibitors from 8 countries, attracted attendees from 42 markets, and resulted in over 30 projects supported by IPI Singapore after the event, TechInnovation 2025 will once again convene innovators, startups, corporates, and government agencies across Asia to showcase emerging technology solutions and forge strategic partnerships. In 2024, notably, 46 percent of visitors were senior management decision-makers, underscoring the event’s position as a high-value marketplace for business and technology leaders.The event focuses on sectors including smart buildings, urban solutions, engineering, digital health, sustainability, advanced manufacturing and AI, ensuring businesses can find solutions tailored to their growth ambitions while engaging directly with innovation leaders, potential collaborators and funding partners. Anchored on the theme Discover, Connect and Collaborate, TechInnovation 2025 offers exhibitors and visitors a platform to showcase ready-to-market technologies, connect with potential partners across borders, and co-create solutions to address real-world challenges faced by businesses.Innovation in Action: Interactive BoothsDebuting this year, TechInnovation 2025 will feature experiential technology showcases, giving select exhibitors the chance to showcase their ready-to-market technologies in a hands-on, interactive format. These interactive spaces are designed to spark conversations, encourage engagements and foster meaningful connections across the show floor. For SMEs, the booths offer a unique opportunity to showcase innovations, build credibility and connect directly with potential partners and customers. The launch responds to strong demand for immersive, real-world demonstrations that make technology tangible and memorable.Call for ExhibitorsTechInnovation 2025 invites technology providers, research institutions, startups and solution developers to participate as exhibitors. Exhibitors will benefit from exposure to thousands of decision-makers and industry leaders, targeted business matching opportunities and media visibility through IPI Singapore’s pre-event publicity and digital campaigns.“TechInnovation brings together enterprises and partners to explore new ideas,” said Michael Goh, Chief Operating Officer of IPI Singapore. “We look forward to welcoming exhibitors whose innovations can support practical business applications and contribute to a more sustainable and competitive future.”About TechInnovation 2025Returning for its 13th edition, TechInnovation 2025 is the flagship event of IPI Singapore, connecting technology seekers and providers across Asia. The event serves as a dynamic marketplace for co-innovation and tech adoption, drawing participation from startups, SMEs, corporates, universities and government agencies.This year’s theme, “Discover, Connect, Collaborate” underscores TechInnovation’s mission to drive growth through discovery, global connection and collaboration. The event will feature over 40 speakers, more than 100 technologies and 3 days of programming designed to scale real-world business innovation. TechInnovation is organised by IPI Singapore, a subsidiary of Enterprise Singapore and catalyst of Singapore’s open innovation ecosystem.TechInnovation® is a registered trademark of IPI Singapore.Learn more at www.techinnovation.com.sg.About IPI SingaporeIPI Singapore is an innovation catalyst that creates opportunities for enterprises to grow beyond boundaries. As a subsidiary of Enterprise Singapore, IPI Singapore accelerates the innovation process of enterprises through access to its global innovation ecosystem and advisory services.With a strong belief that innovation is key to enterprise growth, IPI Singapore provides enterprises with access to innovative ideas and technologies. IPI Singapore also facilitates and supports enterprises' innovation processes, including commercialisation and go-to-market strategies.Learn more at https://www.ipi-singapore.org/Media Contact:Sheree TanManager, Marketing & Communications, PartnershipsIPI Singapore ipi_comms@ipi-singapore.orgTheodore WoonDirectorPINPOINT PR Pte. Ltd.theodore@pinpointpr.global Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - On August 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its unaudited condensed consolidated interim results for the six months ended 30 June 2025 (the "Reporting Period"). During the Reporting Period, the Company delivered outstanding operational performance with revenue of RMB16,418.88 million, representing an increase of 31.7% compared to the same period last year, and realized a profit of RMB752.99 million, representing a year-on-year increase of 80.4%. In the first half of 2025, the Company showed strong profitability and resilience during the accelerated trend of transformation of global renewable energy development.According to SNE Research, the Company’s installed capacity of globally EV batteries in the first half of 2025 increased 22.7%, ranking third domestically and fourth globally, with the monthly installed capacity reaching 4.7GWh. The Company was particularly outstanding in the domestic passenger vehicle market with the market share hitting new highs in June and July, reaching 7.4% and 8.25%, respectively. In the energy storage sector, the Company's growth was even more rapid. According to InfoLink, the Company’s shipment in the first half of the year ranked fourth globally, achieving milestone development in the energy storage sector.Centered on continuous technological breakthroughs and with the launch of multiple major products, in the first half of 2025, the Company maintained its leadership in cutting-edge battery technology with the “UP” battery. At the same time, the Company’s 400Wh/kg solid-liquid hybrid battery is poised for mass production and commercial deployment, while significant progress has been made in the all-solid-state battery—including breakthroughs in R&D and the commissioning of a dedicated production line. CALB’s high-power lithium iron phosphate R46 large cylindrical battery is the first in the industry to achieve mass production and has successfully achieved mass production for the latest PHEV models from Geely and Dongfeng. At the same time, the Company’s next-generation lithium manganese LFP battery product achieves an energy density exceeding 210Wh/kg and will also go into mass production. With improved performance, the product can attain 10%- 80% charging within 15 minutes.In the passenger vehicle market, leveraging exceptional product capabilities, the Company achieved full entry into the world’s top three automakers, namely Volkswagen, Hyundai and Toyota. In the first half of 2025, its 800V 5C batteries achieved a monthly sales volume of over 20,000 packs, which will support models for XPeng, Ledao, Leapmotor, Audi, BAIC, and others, and the 800V 5C high-voltage NCM battery exclusively supports popular models such as XPeng’s new P7 with ultra-long range, helping XPeng’s new P7 create a new world record of driving 3,971km in 24 hours.In the commercial vehicle market, CALB has established a comprehensive product matrix architecture for “ZHIYUAN” batteries, covering all scenarios, all applications, and all capabilities. In the first half of year, the Company’s domestic commercial vehicle installed capacity has increased by 310% year-on-year. CALB is the first in the industry to launch a million-kilometer customized products for light trucks, significantly improving the quality assurance of battery systems and effectively enhancing product competitiveness in the market. Leveraging the outstanding recognition from the light truck field, the Company has established in-depth collaborations with customers such as Chery, Geely, Ruichi, Foton, Dongfeng, Changan, and King Long. In the heavy truck field, the Company has deeply cultivated the market through the scenario-based power consumption design and has achieved full-spectrum collaboration by partnering with customers such as Sinotruk, XCMG, SANY, Shaanxi Automobile, Jiefang, Dongfeng, Lingong, and Liugong.The Company has made significant breakthroughs in the international market, and its energy storage business achieved rapid growth in the first half of year. The 314Ah second-generation long-cycle energy storage cell can achieve an ultra-long service life of 15,000 cycles and high energy efficiency of over 96%, while achieving zero degradation in the first 1,000 cycles, earning high recognition from customers for both the product and delivery capabilities. In terms of the overseas market, the Company has successfully partnered with the largest power plant projects in Latin America and South Africa, entering the supplier lists of several leading developers and power grid companies. Meanwhile, the Company’s next-generation “ZHIJIU” of 588Ah and 600Ah+ large energy storage cells will scheduled for mass production within the year.In addition, the Company is the first in the industry to pass the eVTOL power battery manufacturing compliance review and supports the development of China’s low-altitude economy market by actively exploring emerging markets. At present, the R46 cylindrical battery cell with an energy density of 310Wh/kg is now in mass production for leading eVTOL customers in the industry. At the same time, CALB signed a deepened strategic cooperation agreement with GOVY, under which the two parties will carry out in-depth collaboration in the eVTOL sector and jointly promote the development of standardized eVTOL energy products.Overall, in the first half of the year, CALB focused on the strategy of consolidating its leadership in products and technologies, while accelerating the globalization of its production capacity layout. At present, its battery Pack plant in Thailand has been put into operation, while construction of the Portugal base officially commenced in the first quarter of 2025. Looking ahead, with the further improvement of industrial chain system, the Company is expected to leverage its cross-domain, cross-scenario dynamic storage product matrix to achieve deep synergy in its dynamic storage business, creating cutting-edge product capabilities across all scenarios. At the same time, the Company will continuously explore emerging markets such as rail transit, mining, low-altitude flight, and humanoid robots by offering high-safety, high-reliability, and high-performance product solutions. Furthermore, CALB will continue to advance the implementation of its “energy+” strategy, further consolidating its leading position in the global new energy industry.About CALBCALB is a new energy enterprise specializing in the research, production, sales, and market application development of lithium batteries, battery management systems, and related integrated products and lithium battery materials. As Battery Expert, we aim to build a comprehensive energy operation system, to provide complete product solutions and full life-cycle management for the new energy application market, represented by power and energy storage.Currently, CALB has completed an all-round layout in domestic by setting up industrial bases in Changzhou, Xiamen, Wuhan, Chengdu, Hefei, Jiangmen and Meishan. Meanwhile, CALB has set up bases in Europe and ASEAN, vigorously expanding the layout all over the world to become a global leading enterprise with large-scale intelligent manufacturing capabilities. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 8月27日，中創新航科技集團股份有限公司（「中創新航」或「公司」，股票代碼：3931.HK），公佈截至2025年6月30日止六個月（「報告期」）的未經審計簡明合併中期業績。報告顯示，上半年公司經營表現亮眼，實現營業收入人民幣16,418.88百萬元，較上年同期顯著增長31.7%；期內利潤實現人民幣752.99百萬元，同比大幅增長80.4%，在全球可再生能源發展加速轉型的態勢中展現出強勁的盈利能力與發展韌性。根據權威機構SNE Research統計，中創新航2025年上半年全球動力電池裝車量同比增長22.7%，排名穩居國內第三、全球第四，單月裝車量已達4.7GWh。在國內乘用車市場，公司表現尤為突出，6月、7月市占率連續創下新高，分別達到7.4%和8.25%。儲能領域增速更為迅猛，InfoLink資料顯示，公司上半年儲能電芯出貨量躍升至全球前四，實現里程碑式發展。支撐這一系列成績的，是中創新航技術的持續突破和多款重磅產品的量產落地。上半年，中創新航攜「頂流」電池持續引領技術前沿，公司400Wh/kg固液混合電池產品即將量產配套，全固態電池研發取得突破、生產線貫通投用。此外，公司高功率磷酸鐵鋰R46大圓柱電池實現行業內首家量產配套，成功助力吉利、東風最新混動車型；而下一代210Wh/kg以上能量密度磷酸錳鐵鋰電池產品也即將批量應用，該產品可實現10%電量至80%電量充電時間15分鐘，產品性能進一步提升。在乘用車市場，憑藉卓越的產品實力，中創新航成功實現大眾、現代、豐田全球前三大車企集團全部進入。上半年，其800V 5C電池實現月銷量超2萬台，順利推進配套小鵬、樂道、零跑、奧迪、北汽等多個車型，該超充電池三元版本獨家配套全新小鵬P7，並助力其創下24小時行駛3971公里的全球紀錄。在商用車領域，中創新航構建至遠電池全場景、全覆蓋、全賦能的產品矩陣架構，上半年國內商用車裝車量同比增長310%。公司行業首推輕卡車型百萬公里定製版，大幅提升電池系統質保，獲得業內廣泛認可，目前已與奇瑞、吉利、瑞馳、福田、東風、長安、金龍等知名企業深度合作。在重商領域，公司以場景化電量設計深耕市場，與重汽、徐工、三一、陝汽、解放、東風、臨工、柳工等客戶在多方面達成全方位合作。伴隨著國際市場的重大突破，中創新航上半年儲能業務發展迅猛。其314Ah二代長迴圈儲能電芯憑藉96%以上的能效、15,000次的超長壽命、前1,000次迴圈零衰減的卓越性能獲得國內國際客戶的高度認可，並成功斬獲拉美和南非最大電站專案，進入多家頭部開發商和電網公司的供應商名錄。另外，公司新一代「至久」588Ah、600Ah+儲能大電芯亦將於今年量產。除此之外，作為行業首家通過eVTOL動力電池製造符合性審查的企業，中創新航大力探索新興市場，助力我國低空經濟發展。目前，公司310Wh/kg的R46圓柱電芯已量產配套行業頭部eVTOL企業。同時，中創新航已與廣汽高域簽署深化戰略合作協定，約定在eVTOL領域展開深入合作，共同推進eVTOL電源標準化產品的發展。整體來看，中創新航上半年圍繞「產品與技術領先」戰略，加速全球化產能佈局。目前，泰國Pack工廠已穩定交付，且葡萄牙基地也已於2025年一季度破土動工，未來隨著其產業鏈佈局的進一步完善，中創新航有望憑藉跨領域、跨場景的動儲產品矩陣，實現動儲業務深度協同，全場景打造硬核產品力，同時，持續開拓軌道交通、礦山礦用、低空飛行、人形機器人等新興市場，持續推進「能源+」戰略落地，進一步推進在全球新能源產業中的領先地位。關於中創新航集團有限公司中創新航（3931.HK）是專業從事鋰電池、電池管理系統及相關整合式產品和鋰電池材料的研製、生產、銷售和市場應用開發的新能源高科技企業。作為電池專家，公司致力於構建全方位能源運營體系，為以動力及儲能為代表的新能源全場景應用市場提供完善的產品解決方案和全生命週期管理。目前，公司已建立江蘇、福建、四川、湖北、安徽、廣東等多個產業基地，完成全方位國內產業佈局，同時已設立歐洲產業基地、泰國產業基地，大力拓展海外產業佈局，打造擁有規模化智慧製造實力的國際化領先企業。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月27日 - (亞太商訊 via SeaPRwire.com) - 當前語音 AI 技術正面對「聽懂話中字，難懂話外情」的行業困局 - 傳統語音數據只能覆蓋語義識別，缺乏情緒維度的關鍵信息，導致人機互動始終停留在「功能化」層面。在此背景下，品創控股有限公司（8066.HK）正式宣佈全面戰略升級，旗下核心子公司 CyberMirage 重磅推出「區塊鏈遊戲 + AI 數據採集」一體化平台，更憑藉行業首創的情緒語音數據庫，突破語音 AI 數據瓶頸，為技術邁向「人性化互動」升級提供核心支撐，標誌著公司在數字經濟與人工智能賽道的佈局進入關鍵新階段。會員資源突破：20萬+高黏性用戶為情緒語音數據庫提供「真實場景原料」語音AI的精準度與維度，完全依賴數據的「真實性」與「豐富度」- 人工腳本模擬的語音數據，不僅難以捕捉自然情緒，更無法覆蓋多元生活場景。CyberMirage 創新平台的核心優勢，在於深度激活品創控股20萬+高黏性會員這一核心資產：這些覆蓋不同年齡、職業、地域的會員，在日常互動中已建立信任基礎，能夠在平台場景中自然流露真實情緒。例如，會員在區塊鏈遊戲中完成高難度關卡時的興奮歡呼、遇到挑戰時的緊張溝通、與隊友協作時的積極反應，均會被平台即時採集-這些包含「情緒+語義」的語音素材，正是傳統數據採集模式難以獲取的稀缺資源。同時，平台透過區塊鏈技術實現數據全程可追溯、不可篡改，既保障用戶私隱安全，更確保每一條情緒語音數據的真實性，為情緒語音數據庫的構建奠定「原料根基」。值得關注的是，這些會員此前已在集團電子商務業務中積累了高活躍度，其中逾10萬會員可轉化為語音素材貢獻者。此次平台升級後，將進一步提升情緒語音數據的採集效率與覆蓋維度，形成「用戶沉澱-數據積累-模型優化」的良性循環。技術實力驗證：語音AI項目盈利印證情緒數據「轉化能力」情緒語音數據庫的價值落地，離不開專業技術團隊的支持。CyberMirage 組建的語音AI技術團隊，已具備從「數據提取 - 特徵標注 - 模型訓練」的全鏈條技術能力-今年上半年，團隊借力集團優質客戶資源，成功落地兩項語音AI技術服務項目。一項AI語音技術大模型算法的國家發明專利正在申請中。不僅實現可觀利潤，更從實踐層面驗證了技術轉化能力。更重要的是，團隊透過項目合作積累了豐富的行業需求洞察：如客服領域需重點識別「不滿情緒」以優化服務，智能家居需感知「疲憊狀態」以調整互動模式-這些需求正是情緒語音數據庫的核心應用場景，未來團隊可快速將情緒數據融入現有技術方案，開發出更具競爭力的 「情緒+語義」雙維度AI產品。行業瓶頸突破：首創情緒語音數據庫推動語音AI「從知意到共情」當前語音AI行業的核心瓶頸，在於「情緒數據缺失」導致的互動短板：傳統語音數據只能讓AI「聽懂用戶說甚麼」，卻無法「聽懂用戶心聲」- 客服AI聽不出用戶的不滿，智能家居感知不到主人的疲憊，人形機械人更難以實現「有溫度」的陪伴。據行業調研顯示，70%的用戶認為「AI 無法理解情緒」是人機互動的主要痛點，而目前市場上尚未有成熟的情緒語音數據解決方案。解決人機對話，並讓機器懂得人的情緒和在對話中準確表達所需情緒，是人形機械人走進千家萬戶的充分必要條件。CyberMirage 的情緒語音數據庫，正是針對這一空白的首創性突破：透過區塊鏈遊戲場景採集的語音素材，包含「平常、興奮、失落、緊張、愉悅」等 12 種核心情緒維度，且每種情緒均配對真實場景語義（如勝出遊戲時的「太開心了，終於過關！」、任務失敗後的「唉，下次再努力吧」）。這些數據經技術團隊標注後，可直接用於訓練「情緒+語義」雙維度語音識別 AI 模型，讓AI首次具備「感知情緒、回應情緒」的能力。從應用價值來看，這一突破將徹底重塑語音 AI 的應用邊界：在家庭場景中，配備該模型的人形機械人可通過主人語音情緒，自動調整陪伴模式 - 當識別到疲憊情緒時，主動播放舒緩音樂；在醫療領域，AI 可通過患者語音情緒變化，輔助醫生判斷心理狀態；在教育領域，情緒AI能感知學生學習時的煩躁或專注，動態調整教學節奏。正如行業專家評價：「品創控股的情緒語音數據庫，讓語音AI從『工具』升級為『夥伴』，為整個人機對話行業開啟了人性化互動的新空間。」投資價值凸顯：情緒數據壁壘構築長期增長「護城河」從投資角度來看，品創控股的戰略升級具備三大難以複製的核心優勢，而情緒語音數據庫正是貫穿其中的價值核心：其一，用戶壁壘難以逾越。20萬+高黏性會員不僅為情緒數據提供穩定來源，更能通過圈層傳播吸引更多優質用戶 - 競爭對手若想複製這一資源，需至少 3-5 年的用戶沉澱與信任積累，短期內難以實現；其二，技術轉化能力已獲驗證。上半年兩項語音 AI 項目的盈利，證明團隊能將數據優勢轉化為商業價值，而情緒語音數據庫的加入，將進一步提升產品溢價能力，預計後續定制化 AI 解決方案利潤率可提升15-20%；其三，市場空間持續擴張。隨著人形機械人、智能家居、心理健康等領域對情緒互動需求的增長，情緒語音數據的市場價值將逐年攀升，據估算，2027 年全球情緒 AI 市場規模將突破 500 億美元，品創控股憑藉先發優勢，有望迅速搶佔細分市場份額。值得關注的是，已有3家領先的 AI 應用企業就情緒語音數據庫的合作與品創控股展開磋商，若合作落實，將進一步驗證數據的商業價值，同時為公司帶來穩定的數據流與收入流。未來，品創控股將持續深化「區塊鏈遊戲 + AI 數據採集」模式，推動情緒語音數據庫滲透至更多行業，在實現自身增長的同時，引領語音AI行業從「識別語音」向「理解人心」跨越。 Copyright 2025 亞太商訊 via SeaPRwire.com.

IGG集團2025中期業績摘要及下半年展望：上半年度集團總收入達27.2億港元，同比表現穩健。其中，核心遊戲產品《Doomsday: Last Survivors》和《Viking Rise》分別貢獻約5.2億港元和3.6億港元，APP業務[1]收入達5.3億港元，經典產品《王國紀元》上線九年，發揮穩健，貢獻收入11.5億港元。集團於八月初隆重推出《Fate War》，憑藉卓越的遊戲品質和創新的玩法，三週流水2,000萬港元[2]，為IGG帶來全新的增長動力。集團中期利潤3.2億港元，環比呈增長29%。其中，主營業務利潤（非IFRS指標）[3]貢獻約3.4億港元；投資業務受公允價值變動影響，期內認列未實現減損約0.2億港元。董事會宣派2025年度中期股息每股普通股8.3港仙，以及特別股息每股普通股5.6港仙，合計每股普通股13.9港仙，股息金額約佔2025年上半年利潤的50%。期內，集團回購金額約3,500萬港元，佔中期利潤的11%。集團宣派股息及回購金額合計約佔2025年上半年利潤的61%。香港，2025年8月27日 - (亞太商訊 via SeaPRwire.com) - 全球領先的手機遊戲與移動應用開發商及營運商IGG Inc  （「IGG」，或「集團」，股份代號：799.HK）欣然宣佈集團截至2025年6月30日止之未經審計半年度綜合業績。上半年度遊戲市場競爭加劇，集團不懼挑戰，穩步推進多元化發展。期內，集團實現收入27.2億港元，較去年同期表現穩健。其中，核心遊戲產品《Doomsday: Last Survivors》與《Viking Rise》分別貢獻約5.2億港元和3.6億港元，APP業務收入達5.3億港元，三大項目協同發力，推動收入佔比達52%。集團經典產品《王國紀元》上線九年，穩健長青，為集團貢獻重大收入約11.5億港元。收入區域分佈方面，來自亞洲、歐洲及北美市場的收入分別佔集團收入的42%、35%及19%。上半年度，集團利潤實現3.2億港元，較去年同期大致持平，環比呈增長29%。期內推廣費用同比增加10%，深耕新老用戶再上層樓，延展產品生命週期。其中，主營業務利潤（非IFRS指標）貢獻約3.4億港元；投資業務受公允價值變動影響，期內認列未實現減損約0.2億港元。截至2025年6月30日，本集團以23種不同語言版本向全球發行手遊產品，擁有來自於全球200多個國家和地區的遊戲總用戶數約16億，遊戲月活躍用戶逾1,500萬。集團末日題材策略大作《Doomsday: Last Survivors》自上線以來持續創新，近期推出多人自由組隊玩法「決戰禁區」，顯著提升玩家互動體驗與活躍度。在營銷推廣方面，《Doomsday: Last Survivors》先後與知名電影「環太平洋」及「哥斯拉大戰金剛2」展開IP聯動，備受8,600萬玩家[4]喜愛。此外集團再度集結《王國紀元》、《Doomsday: Last Survivors》、《Viking Rise》等旗下王牌遊戲，開啟「2025 IGG全球巔峰賽」，帶給玩家精彩紛呈的電競體驗。上半年，該遊戲貢獻5.2億港元營收，收入同比增長6%。集團首款維京題材策略新作《Viking Rise》於2022年末上線後，憑藉持續創新的內容更新與營銷策略，全球熱度穩步攀升。期內，遊戲相繼推出全新裝備系統、新賽季等提升玩法深度，帶給玩家新穎體驗。推廣方面，集團積極開展一系列IP聯動，並參與全球知名遊戲展會。截至2025年6月30日，遊戲註冊用戶約5,300萬。上半年，該遊戲貢獻3.6億港元營收，同比增長18%。本集團金牌手遊《王國紀元》上線九週年，歷久彌新，獲Sensor Tower評選為「長青遊戲」[5]。作為集團首款匯集跨平台、多語種、全球玩家即時互動等極具創新玩法的經典遊戲，《王國紀元》自推出以來持續獲得全球玩家青睞，並貢獻穩健收益。截至2025年6月30日，全球註冊用戶達7.7億。期內，遊戲深化IP生態佈局，先後與「秦始皇帝陵博物院」、「可口可樂」及電影「環太平洋」展開重磅聯動，並舉辦線下競技賽事及玩家見面會等活動。依託集團在全球化買量方面的領先優勢，及積累的十多億用戶畫像，APP業務近兩年實現重要戰略突破，締造7,300多萬月活躍用戶，較去年同期增長79%。2025年上半年，APP業務為集團貢獻約5.3億港元營收，同比增長30%，收入佔比進一步提升至約20%，並創造7,300萬港元的可觀利潤，集團佔比約22%。新遊戲方面，集團旗下重磅策略新作《Fate War》於八月初隆重推出，市場反響熱烈。甫一上線，遊戲榮登美國、日本、韓國、德國、法國、英國、意大利等全球22個國家和地區iOS模擬遊戲下載排行榜前三[6]。《Fate War》不僅憑藉高度自由玩法贏得玩家口碑，更獲得蘋果與谷歌雙平台在全球市場重點推薦。遊戲將創新的「模擬經營+策略競技」雙核玩法，深度策略博弈和豐富的賽事體系融為一體。截至2025年8月27日，遊戲註冊用戶120萬，月活躍用戶約120萬，遊戲流水2,000萬港元，展現強勁潛力。股東回饋方面，集團常年通過回購與股息方式回報股東。期內，集團宣派股息及回購金額合計約佔2025年上半年利潤的61%。股息方面，董事會宣派2025年度中期股息每股普通股8.3港仙，以及特別股息每股普通股5.6港仙，合計為每股普通股13.9港仙，股息總金額約佔2025年上半年利潤的50%。上半年，集團回購金額約3,500萬港元，約佔本期利潤的11%。邁入下半年，集團將持續推進遊戲與APP業務增長，更上層樓，並致力於長期穩健盈利。秉承「與時俱進，不忘初心」的企業文化，IGG將不斷深化全球市場的研發及運營，砥礪奮進，破浪向前，繼續為移動互聯網世界打造匠心之作。關於IGG IncIGG集團創立於2006年，是一家全球領先的手機遊戲及移動應用開發商及營運商，總部設在新加坡，於美國、中國、加拿大、日本、韓國、泰國、菲律賓、印尼、巴西、土耳其、意大利及西班牙等地區設有分支機構。IGG爲世界各地的用戶提供多語言、多類型的精品遊戲及移動應用。除Apple、Google和Meta等主要合作夥伴外，集團已與全球逾百家國際平台、廣告商及供應商夥伴佈建長期合作關係。IGG最受歡迎的產品包括《王國紀元》、《Doomsday: Last Survivors》、《Viking Rise》、《時光公主》、《Fate War》等遊戲，以及多元化移動應用。[1]移動應用的開發與運營（簡稱「APP業務」）[2]流水數據截至2025年8月27日[3]主營業務利潤（非IFRS指標）：指扣除投資相關損益後的集團淨利潤。投資相關損益：包括（1）其他金融資產或負債及持有待售資產之公允價值變動及其處置損益，以及股息收入，（2）應佔聯營公司及合營企業的業績、聯營公司及合營企業的權益的減值損失及處置和視同處置的淨損益。[4]註冊用戶數據截至2025年6月30日[5] 來源：第三方機構Sensor Tower發布的《2023年全球年收入超1億美元的長青手遊特徵與趨勢》報告[6] 排名數據：截至2025年8月27日，第三方數據平台data.ai Copyright 2025 亞太商訊 via SeaPRwire.com.

業績摘要：收入增長30%至28.25億港元，創中期歷史新高稅後利潤大幅增長182%至5.5億港元ROE（年化）大幅提升至7.3%宣派中期股息每股0.05港元，派息比率87%傭金及費用、利息收益及交易及投資淨收益均顯著上升，分別達5.41億港元、11.96億港元及10.88億港元業務亮點：數字資産「交易（諮詢）+代理+發行+分銷」全鏈條覆蓋財富管理業務蓬勃發展，分部收入占比約32%，其中經紀業務收入升46%，港股傭金收入飈升131%，跑贏大市企業融資承銷費收入大幅上升85%，配售項目數量市場排名第一中資離岸債主承銷榜承銷數量全市場排名第一，承銷規模中資券商排名第一香港交易所場內衍生品累計成交額中資券商排名第一跨境理財通2.0産品池不斷擴容，君弘全球通APP持續升級，賦能全球資産配置連續10年獲穆迪「Baa2」、標普「BBB+」長期發行人評級，展望「穩定」MSCI ESG 評級A， 連續第三年營運層面碳中和香港，2025年8月27日 - (亞太商訊 via SeaPRwire.com) - 2025年上半年，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」、「集團」或「公司」，股份代號：1788.HK）秉持穩健務實的經營理念，錨定「從穩出發、向新而行」的發展方向，在嚴格把控風險的基礎上，全面提升多元化業務能力，積極推動業務創新，實現了各核心業務協同共進與高質量增長，其中財富管理、企業融資、投資管理等領域尤爲突出，帶動傭金費用、利息收益及交易投資淨收益全面上升。期內，集團收入達28.25億港元，同比上升30%，創中期歷史新高，普通股股東應占溢利爲5.5億港元，同比大幅躍升182%，盈利水平跨越式提升。集團發展成果獲得市場廣泛認可，截至2025年6月30日，公司市值達327億港元，較2024年末大幅躍升200%，在本新聞發布之日，公司市值超過500億港元，市場價值實現顯著提升。爲了回饋投資者的長期認可和支持，公司維持高派息比率，與股東共享發展紅利。董事會宣派截至2025年6月30日止6個月之中期股息每股0.05港元，派息比率87%。財富管理多元深耕，發展與創新雙軌幷進2025年上半年，國泰君安國際積極把握市場機遇，多措幷舉，爲客戶提供多元化産品和服務，財富管理平臺保持股票、債券、基金、衍生品等各類産品協同發展，帶動傭金收入同比大幅上升56%至2.79億港元。集團不斷升級投資交易APP「君弘全球通」，提升客戶體驗，同時加强爲高淨值客戶打造精准的資産配置方案。集團自2024年底率先推出跨境理財通2.0服務以來，不斷豐富産品池，爲境內合資格投資者提供安全便利的一站式投資平臺。同時，集團擇機加大對低風險、高評級與高流動性固定收益資産的配置，爲財富管理産品築牢底層根基，增强市場競爭力。企業融資聚焦重點賽道，債券承銷穩居行業前列國泰君安國際助力多家優質企業在股、債市場融資，帶動配售、承銷及分承銷傭金收益同比大幅上升85%至1.65億港元。2025年上半年，集團共參與150筆債券的發行承銷，同比上升33%，發行總規模約2,588億港元，同比上升38%。根據中證信用科技有限公司債券平臺DMI數據顯示，集團中資離岸債主承銷數量位列全市場榜首，主承銷金額在中資券商中排名第一。股權業務方面，國泰君安國際持續深化與母公司國泰海通的協同聯動，聚焦新能源、機器人、智能駕駛等前沿賽道，顯著提升市場熱點行業的項目覆蓋密度。憑藉在資本運作與項目執行中的專業積澱，集團作爲聯席全球協調人、聯席帳簿管理人助力寧德時代（3750.HK）完成港股IPO項目，同時，協助18家企業成功向聯交所遞交了主板上市申請（不含保密遞交的申請）。上半年，集團亦作爲配售代理人承銷港股再融資項目12筆，位居市場第一，服務知行汽車科技（1274.HK）、晶泰控股（2228.HK）、優必選（9880.HK）、龍蟠科技（2465.HK）等多家知名企業。機構業務穩定發展，産品服務優化創新國泰君安國際與母公司國泰海通緊密協同，整合雙方在境內外市場的資源、渠道和專業優勢，持續爲各類型機構投資者提供跨境、跨資産、跨市場的産品和交易服務，不斷豐富産品矩陣，拓展交易覆蓋範圍。在港股衍生品領域，集團通過持續提升産品設計和交易能力、加大營銷力度，在上半年交易量同比實現顯著增長，港股場內衍生品交易規模位居中資券商第一。截至6月30日，公司金融産品業務規模達417.4億港元，較2024年年底增長4%。2025年上半年，集團首批首日參與債券通（北向通）債券抵押的離岸人民幣債券回購業務。4月，憑藉2024年交易所買賣基金（ETF）交易量的優异表現，集團榮獲聯交所頒發的「交易所買賣産品－交投躍升經紀商」獎項，市場認可度持續提升。數字資産服務全鏈條覆蓋 引領金融行業數字化發展在夯實傳統財富管理業務的基礎上，集團積極拓展全新業務領域。繼2024年獲香港證監會許可開展虛擬資産相關産品（包括場外衍生品）的發售、發行與分銷業務，及獲批准成爲虛擬資産交易介紹代理人後，2025年5月，集團進一步獲確認，可向客戶分銷代幣化證券或就代幣化證券提供意見；6月，集團獲香港證監會准升級現有的第1類（證券交易）受規管活動牌照，透過在香港證監會持牌平臺上開立綜合賬戶的安排，提供虛擬資産交易服務；7月，集團成功發行首筆由中資券商發行的公募數碼原生債券；8月，集團成功發行首批結構化原生通證産品，金融科技創新取得重要突破。至此，集團成爲首家構建起數字資産全方位服務能力的香港中資券商，已實現數字資産「交易（諮詢）+代理+發行+分銷」的全鏈條覆蓋，助力客戶把握財務增長新機遇。堅守ESG理念，綠色金融與低碳運營雙報捷國泰君安國際始終秉持「金融報國，金融爲民，金融向善」的信念，將ESG理念融入幷深化至日常業務營運及管理中，努力打造負責任的綜合金融服務平臺。在綠色金融服務方面，集團持續深耕ESG債券市場，期內完成47筆ESG債券發行，融資規模約達1,027億港元，於DMI中資離岸ESG債券主承銷金額排名中位列中資券商第一名，彰顯了在綠色金融領域的領先地位。低碳運營方面，集團在堅持踐行節能减排的基礎上，通過認購核證碳標準林業項目碳匯資産成功抵銷2024年度範圍1及範圍2碳排放（609.29噸二氧化碳當量），連續第三年實現營運層面碳中和，展現了公司在應對氣候變化方面的堅定承諾和卓越表現。下半年，國泰君安國際將繼續堅持「穩中求進、以進促穩、務實推進」的工作總基調，優化收入結構，推動公司高質量可持續發展。集團將堅持以客戶需求爲導向，全面强化財富管理、企業融資、環球市場等核心業務的綜合服務效能，構建覆蓋機構、企業及個人客戶的全周期金融服務體系，爲各類客戶提供更精准、更多元、更高效的綜合性金融解决方案。同時，集團將在嚴格管控風險的前提下積極推動創新業務的發展，深度融合傳統金融與數字資産服務優勢，構建「一站式數字金融服務平臺」，協助客戶把握Web3.0時代的財富增長新機遇。完整版公告請參閱：https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0827/2025082700593_c.pdf聲明本文稿不構成購買或認購任何證券或金融工具或提供任何投資建議的邀請或要約，幷且其任何部分不構成或依賴與任何合同、承諾或與此相關的投資决策，本文稿亦不構成有關公司之證券或金融工具的建議。本文稿包含有關集團財務狀况、經營業績的若干前瞻性陳述，及集團管理層的若干計劃及目標。這些前瞻性陳述涉及已知和未知的風險、不確定性和其他因素，可能導致實際業績或業績與前瞻性陳述所表達或暗示的任何未來業績或業績截然不同。這些前瞻性陳述是基於集團現在和將來的策略以及集團將來經營的政治和經濟環境的假設。不應將這些前瞻性陳述放在這些前瞻性陳述之上，反映集團管理層截止本次發布之日的觀點。不能保證未來的結果或事件與任何這樣的前瞻性陳述一致。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）, 是中國證券公司國際化的先行者和引領者，公司是首家通過IPO於香港交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地，幷在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球84%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關於國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月27日 - (亞太商訊 via SeaPRwire.com) - 作為香港領先的建築承建商，華營建築有限公司（「華營建築」）重申，「安全至上」是公司營運的基石與不可動搖的核心價值。面對建築行業的固有風險與挑戰，華營建築秉持對員工、合作夥伴及公眾的堅定承諾，近年來不僅深化安全文化，更以前瞻性策略，將尖端科技全面融入日常營運，致力打造更安全、更高效、更可持續的建築環境。今年以來，公司在多個技術領域取得重大進展：- 以BIM技術實現「設計保安全」：公司將建築信息模擬（BIM）技術作為安全管理的數碼核心，在施工開始前，團隊透過創建精密的3D模型進行「數字化預演」，利用軟件的碰撞檢測功能，自動發現不同系統間的潛在衝突，在設計階段就解決問題， 避免反覆在現場修改 ，減少安全隱患 。此外，BIM技術能結合施工進度進行4D模擬，將整個施工過程視覺化，包括大型機械（如塔式起重機）的移動路徑和吊裝範圍等，確保其不會與現有結構碰撞，從設計源頭全面提升工程安全水平 。- 人工智能與自動化流程：華營建築緊貼科技前沿，大力推進人工智能（AI）與機器人流程自動化（RPA）技術在安全管理中的創新應用。作為我司4S智慧工地安全系統的一部分，各施工現場廣泛部署有AI監控攝像頭，即時監測作業人員安全防護裝備佩戴情況、進出車輛車牌權限及環境溫度變化，實現風險預報警與全程可追溯。公司自主研發的Maia AI智慧助手集成企業RAG知識庫，可實現安全規範、歷史文檔一鍵調閱，RPA機器人可實現文檔自動化核查與資料精准錄入，在提高工作效率的同時，有效杜絕人為操作失誤，全面提升工程管理的標準化與智能化水準。- 無人機與三維測繪技術降低高位作業風險：為減少前線人員在複雜環境中的工作危險，公司積極引入無人機及三維測繪（3D Surveying）技術，以排查潛在安全隱患。在大專院校的宿舍項目中，成功運用無人機測繪技術，生成極其精確的3D地形模型，為後續設計與施工提供可靠保障 。此外，針對該項目中一個高約80米的斜坡，項目團隊借助三維測繪技術，結合BIM進行對比分析，迅速優化設計方案，有效解決了複雜的空間難題。- 堅定不移的ESG承諾與安全文化：華營建築將環境、社會及管治（ESG）理念深度融入企業管治及項目生命週期管理，嚴格執行ISO 9001:2015質量管理體系，並透過應用綠色建築技術、管理碳足跡等方式，積極應對行業挑戰。作為總承建商，我們深明自身肩負的重大責任。我們積極響應議會號召，持續推動公司內外的安全文化，特別強調從「要我安全」到「我要安全」、再到「我會安全」的理念轉變，希望同事們由被動接受到主動關注，最終能自發實踐安全行為，做到真正預防事故、降低風險。我們相信，嚴謹的管治（G）和對社會（S）的關懷，是企業長遠發展的基石。華營建築董事及首席營運總監陳德耀先生表示：「我們深刻理解，企業的責任重於泰山，尤其是在守護生命安全方面。今天，我們所採用的每一項創新技術，從AI到BIM，首要的評估標準就是其提升安全的能力。我們的目標不僅是建造宏偉的建築，更是建立一個讓所有工友都能安心工作、平安回家的環境。這是我們對員工、其家人以及整個社會的鄭重承諾。」展望未來，華營建築將繼續以最高的安全標準為依歸，憑藉超過半世紀的專業積澱與不斷創新的科技實力，致力追求業界領先的安全表現，為香港的繁榮發展貢獻更安全、更優質的建築項目。  大專院校的宿舍項目三維地形模型圖，由無人機測繪技術生成，展示了工地、周邊地形及建築物的三維視圖大專院校的宿舍項目，團隊利用三維測繪技術掃描並生成斜坡區域的BIM模型，用以與原設計進行對比分析，有效解決施工中的空間難題關於華營建築有限公司華營建築有限公司於1967年成立，為華營建築集團控股有限公司的間接全資附屬公司，在香港從事建築業多年，累積豐富本地建築市場經驗，成為一所具聲譽及客戶信賴的承建商。2014年1月，浙江省建設投資集團有限公司收購華營，成為華營的最終母公司。2019年10月，華營建築集團控股有限公司於香港聯交所主板上市。華營建築對外承接多項具代表性之工程項目，當中包括白田邨第十三期公營房屋重建項目、啟德1E區1號公營房屋發展項目、運用組裝合成建築法 (MiC) 的洪水橋及荃灣聯仁街過渡性房屋項目、觀塘市中心第二及第三區住宅綜合發展項目、灣仔軒尼詩道1號 (One Hennessy)、麗晶酒店翻新工程、多座數據中心、各大專院校，包括香港中文大學、香港科技大學和香港理工大學在內的教學及科研樓、宿舍等，所承建之項目屢獲殊榮。媒體聯繫黃先生電話：+852 3750 5785郵箱：media@czcgl.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

羅密維爾，伊利諾州, 2025年8月27日 - (亞太商訊 via SeaPRwire.com) - Formerra，身為高效能材料分銷的領導者，今日宣布與 Epaflex S.r.l. 達成協議，指定 Formerra Europe 為 Epaflex 熱塑性聚氨酯 (TPU) 系列在英國與愛爾蘭共和國的首選經銷商。此合作夥伴關係結合了 Epaflex 在 TPU 製造領域超過 30 年的創新傳承，以及 Formerra 在英國／歐盟 REACH 法規合規、在地技術支援與靈活物流方面的深厚專業。此外，此次合作確保電纜、導線、工業、自動化與油氣市場的製程工程師與採購經理，能夠無縫獲取高性能 TPU 等級產品，並享有即時服務與法規指導的支持。「我們很榮幸將 Epaflex 業界領先的 TPU 產品組合納入我們的專業分銷網絡，」Formerra Europe 董事總經理 Ronan Kennedy 表示。「這項協議為英國與愛爾蘭的加工商開啟了真正的機會之窗，透過可靠的供應鏈以及我們客戶所需的技術支援，提供先進的 TPU。」Epaflex 以其 Epamould、Epaline 與 Epamet 工程級 TPU 配方而聞名，這些材料具有高耐磨、耐油、特殊霧面效果以及低溫柔韌性等特性。其應用涵蓋關鍵領域，包括電纜護套、液壓軟管、精密管材與保護膜。再加上公司全新的 Epalite 材料，此產品組合為當今嚴苛的工業環境帶來耐用性、可加工性與設計的多樣化。「與 Formerra 的合作標誌著我們在英國與愛爾蘭拓展的一個重要里程碑，」Epaflex 全球策略行銷經理（彈性體部門）Andrea Martignoni 表示。「他們在當地市場的專業知識，以及對工程師導向服務的承諾，使其成為將 Epaflex 創新帶給此歐洲關鍵地區製造商的理想夥伴。」透過這項協議，Formerra 進一步強化了其在歐洲的佈局，提供無與倫比的產品深度、法規合規指導，以及快速回應能力，以支持客戶最具挑戰性的 TPU 應用需求。關鍵細節：Formerra Europe 獲任命為 Epaflex TPU 系列（Epamould、Epaline、Epamet 和 Epalite）在英國與愛爾蘭的首選經銷商。合作夥伴關係結合了義大利工程的 TPU 等級與 Formerra 在英國／歐盟 REACH 專業知識和靈活服務。目標應用包括電纜／導線護套、液壓軟管、精密管材和保護膜。關於 FormerraFormerra 是領先的工程材料分銷商，將全球頂級聚合物與特種材料製造商與醫療保健、消費品、工業與移動出行等市場的數千家 OEM 與品牌商緊密連結。憑藉技術與商業專業能力，Formerra 提供獨特的產品組合深度、強大的供應鏈實力、深厚的產業知識、卓越的服務、領先的電子商務能力以及創新精神。經驗豐富的 Formerra 團隊協助各行業客戶以全新且更優的方式設計、選擇、加工及開發產品，從而提升性能、生產力、可靠性與永續性。欲了解更多資訊，請造訪 www.formerra.com 。關於 EpaflexEpaflex S.r.l. 總部位於義大利，是熱塑性聚氨酯的領先製造商。三十多年來，Epaflex 為包括電纜與導線、汽車、油氣及消費品等行業開發創新的 TPU 解決方案。其產品組合涵蓋專為耐磨性、柔韌性、耐候性以及特殊表面處理而設計的高性能等級。Epaflex 為 Elachem 集團旗下的私人企業，並設有全球銷售與技術支援中心，以服務世界各地的 OEM 與加工商。媒體聯絡Jackie MorrisFormerra 行銷傳播經理jackie.morris@formerra.com來源: Formerra Copyright 2025 亞太商訊 via SeaPRwire.com.